Balyasny Asset Management
ACRS icon

Balyasny Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Balyasny Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.6M Buy
+3,361,328
New +$11.3M 0.02% 926
2025
Q2 		– Sell
-70,502
Closed -$108K – 2746
2025
Q1 		$108K Buy
+70,502
New +$150K ﹤0.01% 2676
2024
Q3 		– Sell
-13,910
Closed -$15.3K – 2687
2024
Q2 		$15.3K Buy
+13,910
New +$16.3K ﹤0.01% 2483
2023
Q4 		– Sell
-10,511
Closed -$72K – 2437
2023
Q3 		$72K Buy
+10,511
New +$89.8K ﹤0.01% 2142
2023
Q1 		– Sell
-20,503
Closed -$323K – 2583
2022
Q4 		$323K Sell
20,503
-85,644
-81% -$1.38M ﹤0.01% 1971
2022
Q3 		$1.67M Buy
+106,147
New +$1.67M 0.01% 1580
2022
Q2 		– Sell
-209,636
Closed -$3.61M – 2696
2022
Q1 		$3.61M Sell
209,636
-256,764
-55% -$3.5M 0.01% 1089
2021
Q4 		$6.78M Buy
466,400
+304,557
+188% +$4.61M 0.02% 749
2021
Q3 		$2.91M Buy
161,843
+7,423
+5% +$119K 0.01% 1004
2021
Q2 		$2.71M Buy
+154,420
New +$3.51M 0.01% 924
2019
Q1 		– Sell
-315,167
Closed -$2.33M – 1370
2018
Q4 		$2.33M Sell
315,167
-274,833
-47% -$2.83M 0.02% 682
2018
Q3 		$8.57M Sell
590,000
-110,111
-16% -$1.89M 0.04% 538
2018
Q2 		$14M Sell
700,111
-285,865
-29% -$5.28M 0.06% 394
2018
Q1 		$17.3M Buy
985,976
+58,059
+6% +$1.23M 0.07% 363
2017
Q4 		$22.9M Buy
927,917
+461,340
+99% +$11.2M 0.07% 361
2017
Q3 		$12M Buy
466,577
+46,577
+11% +$1.25M 0.05% 444
2017
Q2 		$11.4M Buy
420,000
+21,250
+5% +$578K 0.05% 498
2017
Q1 		$11.9M Buy
398,750
+48,750
+14% +$1.41M 0.06% 431
2016
Q4 		$9.5M Buy
350,000
+250,798
+253% +$6.39M 0.05% 489
2016
Q3 		$2.54M Buy
+99,202
New +$2.1M 0.01% 591

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management's ACRS Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 3,361,328 shares worth $12.6M. The stake represents 0.02% of the portfolio and ranks #926 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in ACRS as recently as Q1 2025.

Balyasny Asset Management first reported a position in ACRS in Q3 2016 and has held it in 20 quarters since. The position peaked at $22.9M in Q4 2017. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Balyasny Asset Management held 3,361,328 shares of Aclaris Therapeutics worth $12.6M as of Q1 2026.
  • Aclaris Therapeutics was a new Balyasny Asset Management position in Q1 2026.
  • Aclaris Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #926 holding.
  • Balyasny Asset Management first reported a position in Aclaris Therapeutics in Q3 2016 and has held it in 20 quarters since.
  • Balyasny Asset Management's Aclaris Therapeutics position peaked at $22.9M in Q4 2017.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.